EMA to quickly review Eli Lilly, Incyte arthritis drug for COVID-19 use – Reuters

EMA to quickly review Eli Lilly, Incyte arthritis drug for COVID-19 use – Reuters

The European Medicines Agency will conduct an accelerated review of Eli Lilly and Co’s rheumatoid arthritis drug Olumiant for hospitalized COVID-19 patients getting oxygen, the agency said on Thursday, as the search for treatment options continues.

Read More…

You May Also Like